Aug 13, 2024 4:01 pm EDT Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
Jul 31, 2024 8:00 am EDT Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence
Jul 29, 2024 8:00 am EDT Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
Jul 25, 2024 8:00 am EDT Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024
Jul 1, 2024 8:00 am EDT Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes
May 29, 2024 8:00 am EDT Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
May 17, 2024 8:00 am EDT Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
May 9, 2024 4:01 pm EDT Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 6, 2024 11:16 am EDT Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
